ATE306555T1 - Replikationsdefizienter adenoviraler tnf vektor - Google Patents

Replikationsdefizienter adenoviraler tnf vektor

Info

Publication number
ATE306555T1
ATE306555T1 AT01950575T AT01950575T ATE306555T1 AT E306555 T1 ATE306555 T1 AT E306555T1 AT 01950575 T AT01950575 T AT 01950575T AT 01950575 T AT01950575 T AT 01950575T AT E306555 T1 ATE306555 T1 AT E306555T1
Authority
AT
Austria
Prior art keywords
adenoviral
tnf
nucleic acid
acid sequence
region
Prior art date
Application number
AT01950575T
Other languages
German (de)
English (en)
Inventor
Douglas E Brough
C Richter King
Imre Kovesdi
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc filed Critical Genvec Inc
Application granted granted Critical
Publication of ATE306555T1 publication Critical patent/ATE306555T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01950575T 2000-06-27 2001-06-27 Replikationsdefizienter adenoviraler tnf vektor ATE306555T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/604,694 US6579522B1 (en) 2000-06-27 2000-06-27 Replication deficient adenoviral TNF vector
PCT/US2001/020536 WO2002000906A2 (en) 2000-06-27 2001-06-27 Replication deficient adenoviral tnf vector

Publications (1)

Publication Number Publication Date
ATE306555T1 true ATE306555T1 (de) 2005-10-15

Family

ID=24420637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01950575T ATE306555T1 (de) 2000-06-27 2001-06-27 Replikationsdefizienter adenoviraler tnf vektor

Country Status (8)

Country Link
US (2) US6579522B1 (enExample)
EP (1) EP1294918B1 (enExample)
JP (2) JP2004501650A (enExample)
AT (1) ATE306555T1 (enExample)
AU (2) AU2001271549B2 (enExample)
CA (1) CA2412637A1 (enExample)
DE (1) DE60114006T2 (enExample)
WO (1) WO2002000906A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1180159B1 (en) * 1999-05-28 2008-09-03 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US6845929B2 (en) * 2002-03-22 2005-01-25 Ali Dolatabadi High efficiency nozzle for thermal spray of high quality, low oxide content coatings
US20030223962A1 (en) * 2002-06-03 2003-12-04 Cornell Research Foundation, Inc. Delivery of gene products to the lung parenchyma via gene transfer to the pleura
EP2168603A1 (en) 2003-11-14 2010-03-31 GenVec, Inc. Therapeutic regimen for treating cancer
NZ546983A (en) * 2003-11-24 2009-05-31 Canji Inc Reduction of dermal scarring
JP2008511336A (ja) * 2004-09-01 2008-04-17 アメリカ合衆国 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法
EP2386564B1 (en) * 2005-10-01 2014-07-16 Charles Stout Regulatable fusion promoters
WO2008112540A2 (en) * 2007-03-09 2008-09-18 Vectorlogics, Inc. Cells for adenovirus vector and protein production
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
WO2011054811A1 (en) 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
US9458473B2 (en) 2010-06-29 2016-10-04 The Johns Hopkins University Compositions and methods for retargeting virus constructs
KR101429696B1 (ko) * 2012-11-21 2014-08-13 국립암센터 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
PL3198009T3 (pl) 2014-09-24 2022-01-24 Salk Institute For Biological Studies Onkolityczne wirusy nowotworowe i sposoby zastosowania
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
JP7430395B2 (ja) 2018-04-09 2024-02-13 ソーク インスティテュート フォー バイオロジカル スタディーズ 複製特質が増強された腫瘍溶解性アデノウイルス組成物
WO2024233783A1 (en) 2023-05-09 2024-11-14 Cornell University Expression cassette coding for vascular endothelial growth factor

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4879226A (en) 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
US5763209A (en) 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
JP3443119B2 (ja) * 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
CA2055168A1 (en) 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
DK0563278T3 (da) 1990-12-20 2000-08-21 Dana Farber Cancer Inst Inc Regulering af geneekspression med ioniserende stråling
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5968735A (en) 1992-11-12 1999-10-19 Max Delbruck-Centrum Fur Molekular Medizin Berlin Vector for the expression of therapy-relevant genes
FR2709309B1 (fr) 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
US5641755A (en) 1994-02-04 1997-06-24 Arch Development Corp. Regulation of x-ray mediated gene expression
US5571797A (en) 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5962424A (en) 1995-02-21 1999-10-05 Arch Development Corporation Methods and compositions for targeting selectins
WO1996027021A1 (en) 1995-03-01 1996-09-06 Cornell Research Foundation, Inc. Interdependent adenoviral vectors and methods of using same
WO1996033746A1 (en) 1995-04-28 1996-10-31 Genetic Therapy, Inc. Treatment of tumors with cells expressing interferons, tumor necrosis factors, or other cytokines
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
JPH11513390A (ja) * 1995-10-06 1999-11-16 アーチ デベロップメント コーポレイション 細胞殺傷のウイルス増強のための方法および組成物
JP3420586B2 (ja) 1995-11-28 2003-06-23 ジェンベク、インコーポレイティッド 細胞への遣伝子導入のためのベクターおよび方法
JP2002512501A (ja) 1996-07-03 2002-04-23 メリアル インコーポレイテッド 外来性ｄｎａを含む組換えイヌアデノウィルス（ｃａｖ）
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
US5981275A (en) 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US6100086A (en) 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
IL120979A0 (en) 1997-06-02 1997-11-20 Interpharm Lab Ltd Glycosylated TNF
US6171787B1 (en) 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
AU750803B2 (en) 1997-10-29 2002-07-25 University Of Pittsburgh Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies
DE19747718A1 (de) 1997-10-29 1999-05-06 Baltzer Axel Wilhelm August Dr Verfahren zur Therapie knochenresorbierender Erkrankungen mit der molekularbiologischen Methode der Gentherapie
AU1377299A (en) 1997-11-03 1999-05-24 Arizona Board Of Regents On Behalf Of The University Of Arizona, The Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
WO1999046371A2 (en) 1998-03-11 1999-09-16 Board Of Regents, The University Of Texas System Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery
JP2002506651A (ja) 1998-03-16 2002-03-05 イントロジェン・セラピューティクス，インコーポレイテッド 多重遺伝子ベクター
AU772963B2 (en) 1998-04-24 2004-05-13 Onyx Pharmaceuticals Adenoviral vectors for treating disease
JP2002518341A (ja) 1998-06-15 2002-06-25 アーチ・デヴェロップメント・コーポレイション 放射線療法と抗血管形成因子の組み合わせ
US6337338B1 (en) * 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer

Also Published As

Publication number Publication date
CA2412637A1 (en) 2002-01-03
US6579522B1 (en) 2003-06-17
JP2004501650A (ja) 2004-01-22
JP2012139220A (ja) 2012-07-26
EP1294918A2 (en) 2003-03-26
WO2002000906A3 (en) 2002-06-06
DE60114006D1 (de) 2006-02-23
EP1294918B1 (en) 2005-10-12
WO2002000906A2 (en) 2002-01-03
AU2001271549B2 (en) 2005-06-09
US20030175245A1 (en) 2003-09-18
DE60114006T2 (de) 2006-07-20
AU7154901A (en) 2002-01-08

Similar Documents

Publication Publication Date Title
AU7154901A (en) Replication deficient adenoviral tnf vector
FI852626A0 (fi) Menetelmä ihmisen tuumorinekroositekijän valmistamiseksi ja sitä koodaava DNA
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
WO1995009241A3 (fr) Therapie genique anticancereuse par modulation de la reponse immunitaire et/ou inflammatoire
ATE295889T1 (de) Gentranskription und ionisierende strahlung: methoden und zusammensetzungen
NO20013701D0 (no) HER-2/neu-fusjonsproteiner
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
WO1995031559A3 (en) Methods of inducing gene expression by ionizing radiation
PT1626058E (pt) Composições e métodos para o diagnóstico de tumores
WO2002012341A3 (en) Her-2/neu fusion proteins
DK1516932T3 (da) Koppevirus med målrettet infektionsspecificitet
PT1200590E (pt) Antigénio transmembranar lectina tipo c expresso em cancro da próstata humano e utilizações do mesmo
WO1999014327A3 (en) Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
WO2003039458A3 (en) TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α
WO1997022695A3 (fr) Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
DK0777499T3 (da) Levende vaccine til behandling af tumorsygdomme
WO2002101076A3 (en) Methods for targeted expression of therapeutic nucleic acid
ATE501255T1 (de) 84p2a9: prostata- und hodenspezifisches protein, das sehr stark bei prostatakrebs vorkommt
DK1313850T3 (da) Nucleinsyre og tilsvarende protein med navnet 85PB3 anvendelige til behandling og påvisning af cancer
ATE391777T1 (de) Verwendung von prohibitin-rns in krebsbehandlung
DE60134956D1 (de) Gene differentiell experimiert in brudtkrebs
ES8802250A1 (es) Un metodo para producir factor de necrosis de tumores.
WO2003047634A3 (en) Nucleic acids and methods for treating ebv-positive cancers

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties